Candriam Luxembourg S.C.A. Has $22.44 Million Holdings in Moderna, Inc. (NASDAQ:MRNA)

Candriam Luxembourg S.C.A. cut its holdings in shares of Moderna, Inc. (NASDAQ:MRNAGet Rating) by 23.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 130,250 shares of the company’s stock after selling 39,014 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Moderna were worth $22,436,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. UMB Bank N A MO acquired a new stake in shares of Moderna in the 4th quarter valued at approximately $135,000. Massachusetts Financial Services Co. MA raised its position in shares of Moderna by 48.6% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 26,861 shares of the company’s stock valued at $6,822,000 after acquiring an additional 8,781 shares during the period. Rafferty Asset Management LLC raised its position in shares of Moderna by 69.4% in the 4th quarter. Rafferty Asset Management LLC now owns 47,288 shares of the company’s stock valued at $12,010,000 after acquiring an additional 19,369 shares during the period. Industrial Alliance Investment Management Inc. acquired a new stake in shares of Moderna in the 4th quarter valued at approximately $29,000. Finally, Pinebridge Investments L.P. raised its position in shares of Moderna by 53.3% in the 4th quarter. Pinebridge Investments L.P. now owns 39,957 shares of the company’s stock valued at $10,148,000 after acquiring an additional 13,886 shares during the period. 60.76% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Moderna

In related news, CEO Stephane Bancel sold 40,000 shares of the firm’s stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $192.94, for a total value of $7,717,600.00. Following the completion of the transaction, the chief executive officer now directly owns 5,411,946 shares of the company’s stock, valued at $1,044,180,861.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CEO Stephane Bancel sold 40,000 shares of the firm’s stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $192.94, for a total value of $7,717,600.00. Following the completion of the transaction, the chief executive officer now directly owns 5,411,946 shares of the company’s stock, valued at $1,044,180,861.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO David W. Meline sold 164 shares of the firm’s stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $173.66, for a total transaction of $28,480.24. Following the completion of the transaction, the chief financial officer now directly owns 2,857 shares of the company’s stock, valued at $496,146.62. The disclosure for this sale can be found here. Over the last three months, insiders sold 557,570 shares of company stock valued at $89,311,945. 17.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of analyst reports. Morgan Stanley cut their price target on shares of Moderna from $199.00 to $197.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 4th. Piper Sandler dropped their target price on shares of Moderna from $348.00 to $214.00 and set an “overweight” rating on the stock in a report on Tuesday, May 17th. SVB Leerink raised their target price on shares of Moderna from $70.00 to $77.00 and gave the stock an “underperform” rating in a report on Monday, August 1st. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “hold” rating to a “buy” rating and raised their target price for the stock from $155.00 to $165.00 in a report on Wednesday. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $227.75.

Moderna Price Performance

Shares of MRNA opened at $141.28 on Friday. The stock has a market capitalization of $56.20 billion, a P/E ratio of 4.31, a P/E/G ratio of 0.78 and a beta of 1.69. Moderna, Inc. has a twelve month low of $115.61 and a twelve month high of $464.85. The company has a 50 day moving average of $158.82 and a 200-day moving average of $151.52. The company has a quick ratio of 1.71, a current ratio of 1.99 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNAGet Rating) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported $5.24 earnings per share for the quarter, topping the consensus estimate of $4.73 by $0.51. Moderna had a net margin of 61.12% and a return on equity of 94.76%. The company had revenue of $4.73 billion during the quarter, compared to analysts’ expectations of $3.95 billion. During the same period last year, the business earned $6.46 EPS. The business’s quarterly revenue was up 8.7% on a year-over-year basis. As a group, equities research analysts forecast that Moderna, Inc. will post 26.42 EPS for the current fiscal year.

Moderna Company Profile

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Further Reading

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.